Apixaban, sold under the brand name Eliquis, has emerged as the leading oral medication for preventing dangerous blood clots in cancer patients — a problem that kills thousands of people every year and complicates treatment for many more. In a landmark trial published in the New England Journal of Medicine, patients taking just 2.5 mg of apixaban twice daily saw their risk of developing a blood clot drop by roughly 59 percent compared to those on a placebo. For the nearly 1.9 million people diagnosed with cancer annually in the U.S. and Canada, this represents a genuine shift in how clinicians manage one of the most common and deadly complications of both cancer itself and the chemotherapy used to fight it. For families navigating dementia care, this matters more than it might first appear.
Older adults with cognitive decline are already at elevated risk for blood clots due to reduced mobility, and when cancer enters the picture — as it does for a significant number of aging adults — the stakes compound rapidly. A pulmonary embolism or deep vein thrombosis can be fatal, and even when it isn’t, it can trigger hospitalization, delirium, and accelerated cognitive decline. Understanding the drugs that prevent these events is not abstract pharmacology. It is practical knowledge for caregivers and patients alike. This article walks through the clinical evidence behind apixaban and other direct oral anticoagulants used in cancer patients, including how doctors identify who needs them, what the newest research says about long-term dosing, and what caregivers should watch for when a loved one is prescribed these medications.
Table of Contents
- How Does Apixaban Prevent Blood Clots in Cancer Patients?
- What the Newest Research Reveals About Long-Term Blood Clot Prevention
- Rivaroxaban and Other Alternatives When Apixaban Isn’t an Option
- How Doctors Decide Which Cancer Patients Need Blood Clot Prevention
- Blood Clot Risks for Dementia Patients With Cancer — What Caregivers Must Watch
- Why Oral Anticoagulants Changed the Standard of Care
- What Comes Next in Blood Clot Prevention for Cancer Patients
- Conclusion
- Frequently Asked Questions
How Does Apixaban Prevent Blood Clots in Cancer Patients?
Cancer creates a hypercoagulable state — the blood becomes stickier and more prone to clotting. This happens through several mechanisms: tumors release substances that activate clotting factors, chemotherapy damages blood vessel walls, and patients are often immobile for long stretches during treatment. The result is venous thromboembolism, which includes both deep vein thrombosis in the legs and pulmonary embolism in the lungs. Apixaban works by directly inhibiting Factor Xa, a key protein in the clotting cascade, effectively thinning the blood enough to prevent dangerous clots from forming without shutting down the body’s ability to stop bleeding entirely. The AVERT trial, conducted across 13 Canadian centers and led by researchers at the University of Ottawa, enrolled 574 ambulatory cancer patients who were receiving chemotherapy. These patients were identified as high-risk using a Khorana score of 2 or higher, a validated tool that predicts clot risk based on cancer type, body mass index, and blood counts.
Only 4.2 percent of patients taking apixaban developed a blood clot within six months, compared to 10.2 percent in the placebo group. The researchers estimated this approach could prevent blood clots in approximately 57,000 people per year across the U.S. and Canada. Before apixaban and similar drugs became available, the standard prevention strategy relied on injectable low-molecular-weight heparin, such as enoxaparin or dalteparin. These injections are effective but burdensome — they require daily self-injection, often cause bruising and injection-site pain, and are difficult for patients with cognitive impairment or limited dexterity to manage on their own. A twice-daily pill is a fundamentally different proposition for a caregiver helping a loved one with both cancer and dementia.
What the Newest Research Reveals About Long-Term Blood Clot Prevention
For cancer patients who have already survived a blood clot, the question of how long to continue anticoagulation — and at what dose — has been a source of clinical uncertainty. The API-CAT trial, published in the New England Journal of Medicine in March 2025 and presented at the American College of Cardiology Scientific Session, addressed this directly. It enrolled 1,766 patients with active cancer who had already completed at least six months of anticoagulant therapy following a deep vein thrombosis or pulmonary embolism. The trial compared reduced-dose apixaban (2.5 mg twice daily) against full-dose apixaban (5 mg twice daily) for an additional 12 months. Recurrent blood clots occurred in just 2.1 percent of the reduced-dose group versus 2.8 percent in the full-dose group, meeting the statistical criteria for non-inferiority.
Critically, clinically relevant bleeding was lower in the reduced-dose group — 12.1 percent compared to 15.6 percent with the full dose. Over a median treatment duration of 11.8 months, the lower dose held up. However, this does not mean every cancer patient should be on a reduced dose indefinitely. The API-CAT trial specifically studied patients who had already tolerated six months of full anticoagulation. Patients who are in the acute phase of a clot, who have certain types of gastrointestinal cancers, or who are on medications that interact with apixaban may need different approaches. The decision to reduce dose should always involve a conversation with the treating oncologist and hematologist, not a unilateral choice by the patient or caregiver.
Rivaroxaban and Other Alternatives When Apixaban Isn’t an Option
Apixaban is not the only direct oral anticoagulant with evidence in cancer patients. Rivaroxaban, marketed as Xarelto, was tested in the CASSINI trial and showed that only 2.62 percent of cancer patients taking the drug developed blood clots, compared to 6.41 percent on placebo. The trial also observed a notable difference in mortality: death occurred in 23.1 percent of the rivaroxaban group versus 29.5 percent in the placebo group, though the study was not specifically powered to draw firm conclusions about survival. Edoxaban, tested in the Hokusai VTE Cancer trial, was shown to be non-inferior to the injectable drug dalteparin for treating cancer-associated blood clots. This gives clinicians a third oral option, which matters when a patient cannot tolerate apixaban due to drug interactions, kidney function, or side effects.
For example, a patient on certain antifungal medications or HIV protease inhibitors may need to avoid apixaban entirely, and having alternatives like rivaroxaban or edoxaban available prevents a return to daily injections. There is an important caveat that caregivers should know: both edoxaban and rivaroxaban carry a specific caution in patients with gastrointestinal or genitourinary cancers. These cancer types are associated with higher bleeding risk in the GI tract, and the oral anticoagulants can increase that risk further. In these cases, clinicians may still prefer injectable heparin or may opt for apixaban at a reduced dose with close monitoring. The choice of drug is not one-size-fits-all, and the type and location of cancer matters enormously.
How Doctors Decide Which Cancer Patients Need Blood Clot Prevention
Not every cancer patient receives preventive anticoagulation. The primary screening tool is the Khorana score, which was used in both the AVERT and CASSINI trials. It assigns points based on the type of cancer (stomach and pancreatic cancers score highest), whether the patient’s body mass index is above 35, and specific blood count abnormalities including elevated platelet counts, high white blood cell counts, and low hemoglobin. A score of 2 or higher identifies patients at high enough risk that preventive therapy is likely to help more than it could harm. The American Society of Clinical Oncology now strongly recommends apixaban for blood clot prevention in cancer patients based on what it classifies as high-quality evidence.
The ASCO guideline updates also recommend apixaban and rivaroxaban as options for extended thromboprophylaxis following cancer surgery, reflecting a broader shift away from injectable-only regimens. For caregivers, this means that if a loved one is diagnosed with cancer and is starting chemotherapy, it is reasonable and appropriate to ask the oncology team whether a Khorana score has been calculated and whether preventive anticoagulation should be discussed. The tradeoff is always bleeding risk versus clotting risk. In the AVERT trial, major bleeding occurred in 2.1 percent of the apixaban group compared to 1.0 percent in the placebo group — a real increase, though all bleeds were treatable and none were fatal. For someone caring for a person with dementia who may not be able to communicate symptoms like unusual bruising, blood in the stool, or prolonged bleeding from a minor cut, this means heightened vigilance is necessary. The benefit of preventing a potentially fatal clot generally outweighs this risk, but the monitoring burden falls squarely on the caregiver.
Blood Clot Risks for Dementia Patients With Cancer — What Caregivers Must Watch
People living with dementia face a compounded set of risks when blood clots enter the picture. Reduced mobility is one of the strongest risk factors for venous thromboembolism, and many people with moderate to advanced dementia spend extended periods sitting or lying down. When cancer and chemotherapy are added, the clotting risk escalates further. At the same time, the cognitive impairment that defines dementia makes it difficult or impossible for the patient to recognize or report warning signs — a swollen, painful leg from a deep vein thrombosis, or the sudden shortness of breath that signals a pulmonary embolism. Caregivers managing anticoagulant therapy in a person with dementia need to be aware of several practical challenges. Medication adherence is paramount: apixaban must be taken twice daily, and missed doses can leave dangerous gaps in protection.
Pill organizers, alarms, and caregiver-administered dosing are essential strategies. Falls are another serious concern — anticoagulants increase the risk that a fall will cause internal bleeding, and people with dementia fall more frequently than the general population. This does not automatically disqualify someone from anticoagulation, but it should prompt a frank conversation with the care team about fall prevention measures. There is also the question of drug interactions. Many people with dementia take medications for behavioral symptoms, sleep disturbances, or co-existing conditions like atrial fibrillation. Some of these drugs, particularly certain antiseizure medications and antifungals, can interact with apixaban and alter its blood levels. A pharmacist review of the full medication list is an underused but critically important step before starting any anticoagulant.
Why Oral Anticoagulants Changed the Standard of Care
For more than a decade, the standard approach to preventing and treating blood clots in cancer patients was daily subcutaneous injection of low-molecular-weight heparin. Drugs like enoxaparin and dalteparin are effective, but they come with real-world drawbacks: the injections are painful, they cause bruising, they require refrigeration, and many patients — especially those with cognitive impairment — simply cannot self-administer them. Caregiver burden was substantial, and adherence rates reflected it. The shift to direct oral anticoagulants like apixaban represents more than pharmacological progress.
It represents a practical improvement in the daily lives of patients and their caregivers. A small pill taken with breakfast and dinner is manageable in a way that a daily injection never was. For families already stretched thin managing dementia care alongside a new cancer diagnosis, this difference is not trivial. It can be the difference between a treatment plan that gets followed and one that quietly falls apart.
What Comes Next in Blood Clot Prevention for Cancer Patients
Research into cancer-associated thrombosis continues to evolve. The API-CAT trial has opened the door to longer-term, reduced-dose strategies that maintain protection while lowering bleeding risk — a particularly promising development for elderly patients and those with comorbidities like dementia. Ongoing studies are examining whether biomarkers beyond the Khorana score can more precisely identify which patients will benefit most, and whether even lower doses or shorter courses might be sufficient for certain cancer types.
There is also growing interest in how anticoagulants may interact with the cancer itself. The mortality difference observed in the CASSINI trial — 23.1 percent in the rivaroxaban group versus 29.5 percent in the placebo group — has spurred investigation into whether blood clot prevention drugs might have anti-tumor properties, though this remains speculative. For now, the practical takeaway is clear: effective, well-tolerated oral drugs exist to prevent one of cancer’s most dangerous complications, and caregivers should not hesitate to advocate for their use when the clinical picture warrants it.
Conclusion
Apixaban has become the frontline defense against blood clots in cancer patients, backed by rigorous trials like AVERT and API-CAT and endorsed by ASCO guidelines. For the roughly 950,000 people diagnosed with cancer each year who could be candidates for this therapy, the reduction in clotting risk — approximately 59 percent in high-risk patients — is substantial. Alternatives like rivaroxaban and edoxaban provide options when apixaban is not appropriate, and the shift from daily injections to oral pills has meaningfully reduced the burden on patients and caregivers alike.
For families managing both cancer and dementia, these drugs deserve particular attention. Blood clots are a leading cause of preventable death in cancer patients, and the people least able to recognize or report symptoms are often those at greatest risk. Asking the oncology team about Khorana score assessment, discussing anticoagulant options, and establishing a reliable medication management plan are concrete steps that caregivers can take. The evidence is strong, the drugs are available, and the conversation with the care team is worth having sooner rather than later.
Frequently Asked Questions
What is the Khorana score and why does it matter?
The Khorana score is a clinical tool that predicts blood clot risk in cancer patients based on cancer type, body mass index, and blood counts including platelet levels, white blood cell counts, and hemoglobin. A score of 2 or higher was used in the AVERT and CASSINI trials to identify patients who would benefit most from preventive anticoagulation. It helps doctors weigh the benefits of blood clot prevention against bleeding risk.
Can apixaban be used in patients who already had a blood clot?
Yes. The API-CAT trial studied 1,766 cancer patients who had already experienced a deep vein thrombosis or pulmonary embolism and completed at least six months of anticoagulant therapy. It found that a reduced dose of apixaban (2.5 mg twice daily) for an additional 12 months was as effective as the full dose at preventing recurrent clots, with less bleeding.
Are there cancer types where these drugs are riskier to use?
Patients with gastrointestinal or genitourinary cancers face a higher risk of bleeding when taking rivaroxaban or edoxaban. In these cases, clinicians may prefer apixaban at a reduced dose or may choose injectable low-molecular-weight heparin instead. The type and location of cancer significantly influence which anticoagulant is safest.
Is it safe to take apixaban if the patient has dementia and falls frequently?
Falls are a real concern because anticoagulants increase bleeding risk from injuries. However, frequent falls do not automatically rule out anticoagulation. The risk of a fatal blood clot often outweighs the risk from falls, but this requires an individualized assessment. Fall prevention strategies — removing tripping hazards, using assistive devices, and ensuring adequate lighting — become especially important.
How does apixaban compare to the older injectable treatments?
Low-molecular-weight heparins like enoxaparin and dalteparin were the previous standard. They are effective but require daily subcutaneous injections, cause bruising, and are difficult for cognitively impaired patients to self-administer. Apixaban, taken as a pill twice daily, provides comparable protection with significantly less caregiver burden and better adherence rates.
What should a caregiver do if a dose of apixaban is missed?
A missed dose should be taken as soon as it is remembered, as long as it is not too close to the next scheduled dose. Doubling up is not recommended. Caregivers managing medications for someone with dementia should use pill organizers, set alarms, and consider supervised dosing to minimize the chance of missed doses, since gaps in therapy leave the patient unprotected.
